发明名称 |
Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef |
摘要 |
The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cyclin D1. |
申请公布号 |
US9109011(B2) |
申请公布日期 |
2015.08.18 |
申请号 |
US200912504463 |
申请日期 |
2009.07.16 |
申请人 |
Baylor Research Institute |
发明人 |
Banchereau Jacques F.;Zurawski Gerard;Flamar Anne-Laure;Cobb Amanda;Mead Holly;Montes Monica;Zurawski Sandra;Oh SangKon |
分类号 |
C07K14/005;C07K14/15;C07K16/28;A61K47/48;A61K39/21 |
主分类号 |
C07K14/005 |
代理机构 |
Norton Rose Fulbright US LLP |
代理人 |
Norton Rose Fulbright US LLP |
主权项 |
1. A composition comprising:
a dendritic cell (DC)-specific antibody or fragment thereof comprising a light chain sequence selected from the group consisting of SEQ ID NO: 24, 25, 26, 27 and 28 and a heavy chain sequence selected from the group consisting of SEQ ID NO: 29 and 30, to which one or more engineered Gag antigens are attached to form an antibody-antigen fusion protein wherein the engineered Gag antigens are less susceptible to proteolytic degradation by eliminating one or more proteolytic sites; and a Nef antigen that is attached to the engineered Gag antigen wherein the composition is able to elicit a human immunodeficiency virus (HIV)-specific T cell immune response to Gag and Nef. |
地址 |
Dallas TX US |